Drugs / Pyruvate (13C)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02911467 | Nov 2016 → Jul 2020 | prostate cancer | Rahul Aggarwal | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02913131 | Oct 2016 → Apr 2021 | prostate cancer | Rahul Aggarwal | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyruvate (13C) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02913131 ↗ |
| Modality | Diagnostic / imaging agent | “hyperpolarized C-13 pyruvate/metabolic magnetic resonance (MR) imaging” NCT02913131 ↗ |